Next Article in Journal
Biochemical and Anatomical Investigation of Sesbania herbacea (Mill.) McVaugh Nodules Grown under Flooded and Non-Flooded Conditions
Previous Article in Journal
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
Previous Article in Special Issue
Compromised Chondrocyte Differentiation Capacity in TERC Knockout Mouse Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2019, 20(8), 1823; https://doi.org/10.3390/ijms20081823

Telomerase-Targeted Cancer Immunotherapy

Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa City, Ishikawa 920-8641, Japan
*
Author to whom correspondence should be addressed.
Received: 17 March 2019 / Revised: 5 April 2019 / Accepted: 10 April 2019 / Published: 12 April 2019
(This article belongs to the Special Issue Role of Telomeres and Telomerase in Cancer and Aging 2019)
  |  
PDF [1022 KB, uploaded 12 April 2019]
  |     |  

Abstract

Telomerase, an enzyme responsible for the synthesis of telomeres, is activated in many cancer cells and is involved in the maintenance of telomeres. The activity of telomerase allows cancer cells to replicate and proliferate in an uncontrolled manner, to infiltrate tissue, and to metastasize to distant organs. Studies to date have examined the mechanisms involved in the survival of cancer cells as targets for cancer therapeutics. These efforts led to the development of telomerase inhibitors as anticancer drugs, drugs targeting telomere DNA, viral vectors carrying a promoter for human telomerase reverse transcriptase (hTERT) genome, and immunotherapy targeting hTERT. Among these novel therapeutics, this review focuses on immunotherapy targeting hTERT and discusses the current evidence and future perspectives. View Full-Text
Keywords: hTERT; T cell; peptide vaccine; dendritic cell; chimeric antigen receptor; immunotherapy hTERT; T cell; peptide vaccine; dendritic cell; chimeric antigen receptor; immunotherapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Mizukoshi, E.; Kaneko, S. Telomerase-Targeted Cancer Immunotherapy. Int. J. Mol. Sci. 2019, 20, 1823.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top